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Human adenoviruses are a common threat to immunocompromised patients, e.g., HIV-positive individu-
als or solid-organ and, in particular, allogeneic stem cell transplant recipients. Antiviral drugs have a lim-
ited effect on adenoviruses, and existing treatment modalities often fail to prevent fatal outcome.
Silencing of viral genes by short interfering RNAs (siRNAs) holds a great promise in the treatment of viral
infections. The aim of the present study was to identify adenoviral candidate targets for RNA interfer-
ence-mediated inhibition of adenoviral replication. We investigated the impact of silencing of a set of
early, middle, and late viral genes on the replication of adenovirus 5 in vitro. Adenovirus replication
was inhibited by siRNAs directed against the adenoviral E1A, DNA polymerase, preterminal protein
(pTP), IVa2, hexon, and protease genes. Silencing of early and middle genes was more effective in inhib-
iting adenovirus multiplication than was silencing of late genes. A siRNA directed against the viral DNA
polymerase mRNA decreased viral genome copy numbers and infectious virus progeny by several orders
of magnitude. Since silencing of any of the early genes directly or indirectly affected viral DNA synthesis,
our data suggest that reducing viral genome copy numbers is a more promising strategy for the treatment
of adenoviral infections than is reducing the numbers of proteins necessary for capsid generation. Thus,
adenoviral DNA replication was identiﬁed as a key target for RNAi-mediated inhibition of adenovirus
multiplication. In addition, the E1A transcripts emerged as a second important target, because its knock-
down markedly improved the viability of cells at late stages of infection.
 2012 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Human adenoviruses are double-stranded DNA (dsDNA) viruses
associated with a wide range of human diseases. They are mainly
responsible for self-limiting respiratory and intestinal infections,
and predominantly affect children and young adults (Lenaerts
et al., 2008). However, more severe manifestations, including hem-
orrhagic cystitis, nephritis, pneumonia, hepatitis, enterocolitis, and
disseminated disease, are observed in immunocompromised pa-
tients, such as solid-organ and, in particular, allogeneic stem cell
transplant recipients (Echavarria, 2008; Ison, 2006; Kojaoghlanian
et al., 2003). These manifestations can be life-threatening or even
lethal. In the case of disseminated disease, mortality rates as high
as 80% have been reported (Blanke et al., 1995; Hale et al., 1999;
Howard et al., 1999; Lion et al., 2003; Munoz et al., 1998). Severe
manifestations are most commonly associated with serotypes from
species B and C (Kojaoghlanian et al., 2003), with a high prevalencell interfering RNA.
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-NC-ND license. of species C in certain geographical areas (Ebner et al., 2006; Lion
et al., 2003, 2010).
In the immunocompetent host, a severe manifestation of ade-
novirus infection is epidemic keratoconjunctivitis (EKC). This is
predominantly associated with serotypes 8, 19, and 37 (all belong-
ing to species D), is highly contagious, and can have severe conse-
quences on visual acuity (Gordon et al., 1996). Besides, EKC is
generally associated with signiﬁcant morbidity, which results in
considerable economic losses.
The most common agents for treating adenovirus infections are
ribavirin and cidofovir. However, apparent clinical efﬁcacy has
been demonstrated only for cidofovir. Although cidofovir is widely
used, its activity is limited and insufﬁcient to completely prevent
fatal outcomes among hematopoietic stem cell transplant recipi-
ents (Lenaerts et al., 2008; Lindemans et al., 2010; Ljungman
et al., 2003; Symeonidis et al., 2007; Yusuf et al., 2006). Further-
more, concomitant recovery of the immune system may be neces-
sary for complete adenovirus clearance (Chakrabarti et al., 2002;
Heemskerk et al., 2005; Lindemans et al., 2010). Cidofovir displays
signiﬁcant nephrotoxicity and limited bioavailability, and this has
prompted the development of improved derivatives. However,
the effectiveness of these compounds is still under evaluation
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growing numbers of immunosuppressed patients, the develop-
ment of alternative anti-adenovirus treatment options is required
to decrease adenovirus-mediated mortality among immunocom-
promised patients, and also to decrease economic losses caused
by milder forms of adenovirus-related disease.
RNA interference (RNAi) is a post-transcriptional mechanism of
gene silencing conserved among eukaryotic cells (Carthew and
Sontheimer, 2009; Ghildiyal and Zamore, 2009; Huntzinger and
Izaurralde, 2011; Hutvagner and Simard, 2008; Kawamata
and Tomari, 2010). It is mediated through small double-stranded
RNAs (dsRNAs), of 21–25 nt in length, which guide the RNA-
induced silencing complex (RISC) to the respective target mRNAs
(Fire et al., 1998). Depending on the degree of complementarity be-
tween the so-called antisense (or guide) strand of the dsRNA and
target mRNA, RNAi can bring about the cleavage of the mRNA
(in the case of full or nearly full complementarity), accelerated
degradation (as a consequence of deadenylation), or translational
repression. Following the discovery that the introduction of syn-
thetic small interfering RNAs (siRNAs) into cells can trigger RNAi
(Elbashir et al., 2001), this mechanism was rapidly harnessed as
a tool to silence disease-associated human, and also viral genes
(Davidson and McCray, 2011). Since then, siRNA-mediated silenc-
ing of viral genes has been employed to inhibit the replication
of a variety of DNA and RNA viruses, in vitro and also in vivo
(Arbuthnot, 2010; Haasnoot et al., 2007; Zhou and Rossi, 2011).
Adenoviruses contain a linear dsDNA genome, 36 kb long. The
ﬁrst gene to be expressed during the infection cycle is E1A. This
gene has a central role, because it reprograms the cell in a way that
promotes efﬁcient virus replication (Berk, 2005; Pelka et al., 2008;
Zhao et al., 2003). Deletion of E1A renders adenoviruses replication
deﬁcient. E1A expression ultimately leads to the activation of other
early and late promoters and triggers the onset of viral DNA repli-
cation. Viral DNA replication is dependent on three viral proteins:
the viral DNA polymerase; the preterminal protein (pTP); and the
DNA-binding protein (DBP) (de Jong et al., 2003). Besides creating
dsDNAs for packaging into capsids (accomplished with the help of
the IVa2 protein) (Zhang and Imperiale, 2003), replication of the
adenoviral genome activates the expression of other viral genes,
e.g., IVa2 (Flint, 1986; Iftode and Flint, 2004) and genes transcribed
from the major late promoter (MLP) (Shaw and Ziff, 1980). Upreg-
ulation of major late (ML) gene expression also involves the IVa2
protein (Tribouley et al., 1994), and results in the synthesis of gene
products that primarily constitute structural components of the
virion or are involved in its assembly. The major component of
the capsid is the hexon protein (Russell, 2009). Capsid maturation
requires the action of adenovirus protease, also called adenain
(Webster et al., 1989). This protein, which is an integral part of
the mature virion, is also required for disassembly of the virion
upon virus entry, and consequently for release of the viral DNA
(Greber et al., 1996).
In vitro silencing of adenoviral genes by siRNAs has been dem-
onstrated for an adenovirus (Ad) 11 strain (2K2/507/KNIH; species
B; isolated in Korea) (Chung et al., 2007), and also for a mutant
strain of Ad5 (species C) lacking the E1B and E3 genes (Eckstein
et al., 2010). In the case of Ad11, siRNAs directed against E1A were
reported to result in an overall reduction of plaque-forming capac-
ity. For the Ad5 mutant strain, siRNAs targeting the E1A, IVa2, and
hexon mRNAs were evaluated, and the IVa2 mRNA-targeting siRNA
was reported to most efﬁciently decrease virus production. A pro-
tective effect on cell viability was observed only when the IVa2
mRNA-targeting siRNA was combined with an E1A mRNA-directed
siRNA and administered at high concentration. The Ad5 mutant
virus used represented a rather artiﬁcial test system, in that it
lacked the E1B genes which, when present, prevent premature cell
death, thereby prolonging virus replication and promoting virallate mRNA export from the nucleus (Blackford and Grand, 2009;
Flint and Gonzalez, 2003; Subramanian et al., 1995; Woo and Berk,
2007). Together with the fact that the E1A gene was expressed
from an artiﬁcial minimal CMV promoter autoactivated by E1A
(Fechner et al., 2003), these differences from the wild-type virus
make it somewhat difﬁcult to accurately assess the potential of
siRNA-mediated adenovirus gene silencing as a strategy for inhib-
iting adenovirus multiplication.
Here, we investigated the impact of siRNA-mediated adenovirus
gene silencing on the replication of wild-type adenovirus. We ex-
panded the panel of potential adenoviral targets, by evaluating siR-
NAs directed against the Ad5 E1A, DNA polymerase, pTP, IVa2,
hexon, and protease mRNAs. Based on our in vitro results, we pro-
pose that the adenoviral mRNAs originating from genes which are
essential for viral DNA replication (i.e., the DNA polymerase and
pTP (and potentially the DBP) genes are promising targets for
RNAi-mediated inhibition of adenovirus multiplication. Moreover,
we demonstrate that highly potent E1A mRNA-directed siRNAs,
which are also able to inhibit virus replication (albeit to a lesser ex-
tent than the DNA polymerase mRNA-directed siRNA), are capable
of concomitantly delaying cell death, without the need for combi-
nation with other siRNAs. This distinct mode of inhibition may be
exploited in vivo for siRNA-mediated attenuation of virus release
and, consequently, virus spread.2. Materials and methods
2.1. Cell culture and virus production
HEK293 (human embryonic kidney; ATCC CRL-1573) and A549
(human epithelial lung carcinoma; ATCC CCL-185) cells were culti-
vated in Dulbecco’s Modiﬁed Eagles Medium (DMEM) with
stabilized glutamine (PAA Laboratories, Pasching, Austria) supple-
mented with 10% fetal bovine serum (FBS; PAA Laboratories) in a
humidiﬁed 5% CO2 atmosphere at 37 C. Ad1 (ATCC VR-1), Ad2
(ATCC VR-846), and Ad6 (ATCC-VR6), were ampliﬁed in A549 cells;
Ad5 (ATCC VR-5) was ampliﬁed in HEK293 cells. Virus puriﬁcations
were performed by standard CsCl density gradient ultracentrifuga-
tion. Infectious virus particle titers were determined on A549 cells
by 50% tissue culture infective dose (TCID50) assays.2.2. Vector construction
For the construction of vectors employed in dual-luciferase
assays, parts of the Ad5 genome were ampliﬁed by PCR using prim-
ers speciﬁc for E1A (E1A-f1 50-CGACACCGGGTTTAAACATGAGACA
TATTATCTGCCAC-30 and E1A-r1 50-CAACTCATTGTTTAAACAAAGG
CGTTAACCA-30; annealing temperature [Ta]: 50 C), DNA polymer-
ase (Pol-f1 50-ACTCATATGGCCTTGGCTCAAGCTCACCGGGC-30 and
Pol-r1 50-ACTAGATCTACGGCATCTCGATCCAGCATATC-30; Ta: 55 C),
pTP (pTP-f3 50-CTTTTGCACGGTCTCGAGCGTCAACGATTGCGC-30 and
pTP-r3 50-GTGTCCTTGGATGCGGCCGCTAAAAGCGGTGACGCGGG-30;
Ta: 65 C), IVa2 (IVa2-f1 50-CACCGGCTCGTTTAAACCAGAGGGCGAAG
AC-30 and IVa2-r1 50-AAACATAAAGTTTAAACCAGACTCTGTTTGGAT-
30; Ta: 50 C), hexon (Hex-f1 50-CCGCTTCTCGAGATGGCTACCCCTTC
GATGATG-30 and Hex-r1 50-TGTTGCGCGGCCGCTTATGTTGTGGCG
TTGCCGG-30; Ta: 57 C), and protease (Prot-f1 50-CAAGCAACAGTTT
AAACAGCTGCCGCCATGG-30 and Prot-r1 50-AAATAAGTTTAAACGCC
TTTATTGAAAGTGTCTC-30; Ta: 50 C). The PCR reactions were
performed in a total volume of 50 lL containing 10x PCR buffer
(Peqlab), 400 lM dNTPs, 1 lM of each primer, 4 mM MgSO4 and
2.5 U of Pwo-DNA-Polymerase (Peqlab). The cycling parameters
consisted of a total of 30 cycles of denaturing at 95 C for 1 min,
followed by annealing at the appropriate temperature for 1 min
and extension at 72 C for 2 min. The PCR products were subjected
D. Kneidinger et al. / Antiviral Research 94 (2012) 195–207 197to agarose gel electrophoresis, stained with ethidium bromide, and
visualized on a UV transilluminator. The PCR fragments were in-
serted into the PmeI site (E1A, IVa2, protease fragments), XhoI
and NotI sites (pTP, hexon), or NdeI and BglII sites (DNA polymer-
ase) of psiCHECK-2 (Promega, Mannheim, Germany), all located
within the 30 UTR of the Renilla luciferase gene. The resulting vec-
tors were named psiCHECK-E1A, psiCHECK-pol, psiCHECK-pTP,
psiCHECK-IVa2, and psiCHECK-hex. Restriction enzymes and
DNA-modifying enzymes were purchased from Fermentas (St.
Leon-Rot, Germany) or New England Biolabs (Frankfurt am Main,
Germany). PCR reactions were performed with Pwo DNA polymer-
ase obtained from Roche Diagnostics (Vienna, Austria).
2.3. Nucleic acid extraction
Circular plasmid DNA was extracted with QIAprep Spin Mini-
prep Kits (QIAGEN, Hilden, Germany), EasyPrep Pro Plasmid Mini-
prep Kits (Biozym, Oldendorf, Germany), or HiSpeed Plasmid Midi
Kits (QIAGEN). PCR products were puriﬁed with a QIAquick PCR
Puriﬁcation Kit (QIAGEN). Adenoviral DNA was isolated from cells
using a QIAamp DNA Blood Mini Kit (QIAGEN). Total RNA was iso-
lated using an RNeasy Mini Kit (QIAGEN).
2.4. SiRNAs
With the exception of pTP-si1, pTP-si2, pTP-si3, and pTP-si4, all
siRNAs (Table 1) were obtained from Invitrogen (LifeTechnologies
Austria, Vienna, Austria). They represented 25-mer, blunt-ended
siRNAs carrying the Invitrogen ‘‘Stealth’’ modiﬁcation. Due to the
type of chemical modiﬁcation, only the antisense strand can
participate in RNAi, thus avoiding not only unwanted, sense strand-
mediated, off-target effects but also preventing any possible inter-
ference of the sense strand with adenoviral transcripts generated
from the opposite viral DNA strand not intended to be targeted.
Besides, this type of modiﬁcation (frequently present in similar
versions in commercial siRNAs) can increase the intracellular
half-life of siRNAs and reduce their cytotoxicity. The pTP-si1 to
pTP-si4 siRNAs (obtained from Ambion/LifeTechnologies Austria,
Vienna, Austria) were 21-mer, unmodiﬁed siRNAs carrying two
nucleotide (nt) TT overhangs at their 30 ends and were also in-
cluded in our experiments. As negative controls, two distinct uni-
versal non-targeting siRNAs (Invitrogen, Ambion), matching the
type of design of the respective targeting siRNAs, were employed.
SiRNAs were designed using the Invitrogen BLOCK-iT™ RNAi
Designer or Dharmacon siDESIGN tools and target site accessibility,
as calculated by RNAxs (http://rna.tbi.univie.ac.at/cgi-bin/RNAxs),
was taken into account.
2.5. Dual-luciferase assay-based screening for functional siRNAs
1.4e+05 HEK293 and 3e+04 A549 cells were seeded into the
wells of 96-well plates, and reverse transfected with 50 ng of indi-
vidual dual-luciferase reporter vectors and 30 nM targeting or non-
targeting control siRNA using Lipofectamine 2000 (Invitrogen/Life-
Technologies Austria, Vienna, Austria). Brieﬂy, for each well 0.5 lL
Lipofectamine 2000 was diluted with 24.5 lL OptiMEM medium
(Invitrogen/LifeTechnologies Austria, Vienna, Austria), and after
5 min of incubation, 25 lL diluted Lipofectamine 2000 was mixed
with 25 lL of a speciﬁc siRNA/reporter vector mix (diluted in Opti-
MEM). After 20 min of incubation, the mixes were pipetted directly
into the wells of a 96-well plate and freshly harvested cells were
added. After 24 h of incubation, medium was exchanged and cells
were incubated for another 24 h. Culture conditions were as de-
scribed above. Fireﬂy and Renilla luciferase activities were deter-
mined at 48 h post-transfection using the Dual-Glo luciferase
assay (Promega), according to the manufacturer’s instructions.Brieﬂy, 75 lL of Dual-Glo Reagent was added to cells grown in
75 lL medium, and after 10 min of incubation at room tempera-
ture, ﬁreﬂy luciferase activity was measured. Next, one volume of
Dual-Glo Stop & Glo reagent was added to each well, plates were
incubated for an additional 10 min at room temperature, and even-
tually, Renilla luciferase activity was determined. Luminescence
was measured on a Wallac Victor 1420 Multilabel Counter (Perkin
Elmer Austria, Brunn am Gebirge, Austria). Knockdown rates were
calculated by normalizing Renilla luciferase activities to ﬁreﬂy
luciferase activities, and comparing dual-luciferase ratios between
targeting and non-targeting control siRNAs.
2.6. Determination of mRNA levels
1.25e+05 A549 cells were seeded into the wells of 24-well
plates and reverse transfected with siRNAs at a concentration of
10 nM. Volumes of transfection mixes were adjusted to the 24-well
plate format. Brieﬂy, for each well 1 lL Lipofectamine 2000 was di-
luted with 49 lL OptiMEM medium (Invitrogen/LifeTechnologies
Austria, Vienna, Austria), and after 5 min of incubation, 50 lL di-
luted Lipofectamine 2000 was mixed with 50 lL of a speciﬁc siRNA
diluted in OptiMEM. Transfection conditions were otherwise as de-
scribed under 2.5. After 24 h of incubation, medium was ex-
changed and cells were infected with Ad5 at an multiplicity of
infection (MOI) of 0.01 TCID50/cell, and total RNA was isolated at
24 h post-infection using an RNeasy Mini Kit (QIAGEN). Residual
DNA was removed with RQ1 DNase (Promega), and reverse tran-
scription was carried out using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Expression levels of the
E1A-12S, E1A-13S, DNA polymerase, pTP, IVa2, hexon, and prote-
ase genes were determined by TaqMan real-time quantitative
PCR (qPCR), using the LightCycler 480 Probes master mix (Roche
Diagnostics) and primer/probe sets speciﬁc for E1A-13S (E1A
289R-cDNA-f1 50-GCATGTTTGTCTACAGTCCTGTGTC-30, E1A 289R-
cDNA-r1 50-GGCGTCTCAGGATAGCAGGC-30, and E1A 289R-cDNA-p1
50-AGGCTCCGGTTCTGGCTCGGG-30), E1A-12S (E1A 12S-cDNA-f1
50-AGGATGAAGAGGGTCCTGTGTCT-30, E1A 289R-cDNA-r1 50-GGCG
TCTCAGGATAGCAGGC-30, and E1A 289R-cDNA-p1 50-AGGCTCCG
GTTCTGGCTCGGG-30), DNA polymerase (Pol-cDNA-f1 50-ATGGCCT
TGGCTCAAGCTC-30, Pol-cDNA-r1 50-GCGTAGGTTGCTGGCGAAC-30,
and Pol-cDNA-p1 50-CGCCTCTGCGTGAAGACGACGG-30), pTP (pTP-
cDNA-f2 50-AAACCAACGCTCGGTGCC-30, pTP-cDNA-r2 50-GGACGC
GGTTCCAGATGTT-30, and pTP-cDNA-p2 50-CGCGCGCAATCGTTG
ACGCT-30), IVa2 (IVa2-cDNA-f1 50-GGAAACCAGAGGGCGAAGA-30,
IVa2-cDNA-r1 50-AGGGTCCTCGTCAGCGTAGTC-30, and IVa2-cDNA-p1
50-CTTGAGGCTGGTCCTGCTGGT-30), hexon (Hex-cDNA-f1 50-CAGTC
ACAGTCGCAAGAGGAGC-30, Hex-cDNA-r1 50-AGGTACTCCGAGG
CGTCCTG-30, and Hex-cDNA-p1 50-ACCACTGCGGCATCATCGAAG
GG-30), and protease (Prot-cDNA-f1 50-TCACAGTCGCAAGTCTTTG
ACG-30, Prot-cDNA-r1 50-GCGGCAGCTGTTGTTGATG-30, and Prot-
cDNA-p1 50-CCGAGAAGGGCGTGCGCAGGTA-30). The speciﬁcity of
the primers employed (i.e., covered exon–exon junctions) enabled
them to discriminate between overlapping transcripts or tran-
scripts originating from the (+) or () strand, respectively. Ad5
gene expression levels were normalized to GAPDH expression lev-
els, which were previously proven to remain unchanged upon Ad5
infection under the selected experimental conditions. GAPDH
expression was determined with the primer/probe set GAPDH-f1
50-TGCACCACCAACTGCTTAGC-30, GAPDH-r1 50-GGCATGGACTGTG
GTCATGAG-30, and GAPDH-p1 50-CCTGGCCAAGGTCATCCATGACAA
CTT-30. All q PCR assays were set up in 96-well plates and con-
tained 1 LightCycler 480 Probes master mix (Roche Diagnostics,
Vienna, Austria), 500 nM of forward and reverse primers, each,
100 nM of probe, and 1 lL of cDNA in a total volume of 20 lL.
For the detection of GAPDH cDNA, 300 nM of forward and reverse
primers, each, and 1 lL of 1:10 diluted template cDNA were used
Table 1
siRNA sequences.
Name Sequence (sense/antisense) Target site in Ad5a Target Serotype speciﬁcityb
E1A-si1 50-AACGAGGAGGCGGUUUCGCAGAUUU-30 731–755 E1A 1, 2, 5, 6
50-AAAUCUGCGAAACCGCCUCCUCGUU-30
E1A-si2 50-CAGGAAGGGAUUGACUUACUCACUU-30 782–806 E1A 1, 5
50-AAGUGAGUAAGUCAAUCCCUUCCUG-30
E1A-si3 50-CCUGUGUCUAGAGAAUGCAAUAGUA-30 1333–1357 E1A 2, 5, 6
50-UACUAUUGCAUUCUCUAGACACAGG-30
E1A-si3_scr 50-CCUUGUCGAGAAAGUACUAAUGGUA-30 – – –
50-UACCAUUAGUACUUUCUCGACAAGG-30
Pol-si1 50-CAAGACCCGCUUACCUUCUACUGCA-30 7782–7806 DNA pol 1, 2, 5, 6
50-UGCAGUAGAAGGUAAGCGGGUCUUG-30
Pol-si2 50-CAACGUCUUCCAGCGUCCAACCAUA-30 6928–6952 DNA pol 1, 2, 5, 6
50-UAUGGUUGGACGCUGGAAGACGUUG-30
Pol-si3 50-TGUCUCAGAGUGGUCCGAGUUUCUA-30 5818–5842 DNA pol 5
50-UAGAAACUCGGACCACUCUGAGACA-30
Pol-si4 50-CGUCUUCCAGCGUCCAACCAUAUCA-30 6925–6949 DNA pol 1, 2, 5, 6
30 UGAUAUGGUUGGACGCUGGAAGACG-30
Pol-si5 50-CAGCGUCCAACCAUAUCAUCCAACU-30 6918–6942 DNA pol 2, 5, 6
50-AGUUGGAUGAUAUGGUUGGACGCUG-30
Pol-si6 50-GCGUCCAACCAUAUCAUCCAACUCA-30 6916–6940 DNA pol 2, 5, 6
50-UGAGUUGGAUGAUAUGGUUGGACGC-30
Pol-si2_scr 50-CAACUUUCCGAGCCUACCACGCAUA-30 – – –
50-UAUGCGUGGUAGGCUCGGAAAGUUG-30
IVa2-si1 50-ACAUGCGAGUCAGGGACAUGCUUAA-30 5013–5037 IVa2 5
50-UUAAGCAUGUCCCUGACUCGCAUGU-30
IVa2-si2 50-AAAUACAGUCCAAGAUGCAUCUCAU-30 4410–4434 IVa2 1, 2, 5, 6
50-AUGAGAUGCAUCUUGGACUGUAUUU-30
IVa2-si3 50-CAUCCCAGCUUAACCGCUUUGUAAA-30 4368–4392 IVa2 1, 2, 5, 6
50-UUUACAAAGCGGUUAAGCUGGGAUG-30
Hex-si1 50-UAGAAACUCGGACCACUCUGAGACA-30 5818–5842 Hexon 5
50-AUUUAUACCAGAAUAAGGCGCCUGC-30
Hex-si2 50-GAGAACUAAUGGGCCAACAAUCUAU-30 19776–19800 Hexon 5
50-AUAGAUUGUUGGCCCAUUAGUUCUC-30
Hex-si3 50-GCCUCAGAAGUUCUUUGCCAUUAAA-30 20527–20551 Hexon 5
50-UUUAAUGGCAAAGAACUUCUGAGGC-30
Hex-si4 50-CCGUCAGGUGGUGGAUGAUACUAAA-30 21247–21271 Hexon 5
50-UUUAGUAUCAUCCACCACCUGACGG-30
Prot-si1 50-GAGCAGGAACUGAAAGCCAUUGUCA-30 21745–21769 Protease 2, 5, 6
50-UGACAAUGGCUUUCAGUUCCUGCUC-30
Prot-si2 50-AAGAUCUUGGUUGUGGGCCAUAUUU-30 21770–21794 Protease 2, 5, 6
50-AAAUAUGGCCCACAACCAAGAUCUU-30
Prot-si3 50-UCAAGCAGGUUUACCAGUUUGAGUA-30 21972–21995 Protease 1, 2, 5, 6
50-UACUCAAACUGGUAAACCUGCUUGA-30
pTP-si1 50-CCGCCUACUUUAAUUACAUTT-30 9805–9823 pTP 1, 2, 5, 6
50-AUGUAAUUAAAGUAGGCGGTT-30
pTP-si2 50-GAGGAGAUUGAAGAAGAAGTT-30 9359–9377 pTP 1, 2, 5, 6
50-CUUCUUCUUCAAUCUCCUCTT-30
pTP-si3 50-GGUAGAAAGGCUCAUGCAATT-30 9945–9963 pTP 1, 2, 5, 6
50-UUGCAUGAGCCUUUCUACCTT-30
pTP-si4 50-CGAAAUUGAUUCUGUCGAATT-30 8796–8814 pTP 1, 2, 5, 6
50-UUCGACAGAAUCAAUUUCGTT-30
pTP-si5 50-GACUACGUAUUUGACUCGAGGGCUU-30 10289–10313 pTP 5
50-AAGCCCUCGAGUCAAAUACGUAGUC-30
pTP-si6 50-CGGUAGAAAGGCUCAUGCAAGACUA-30 9940–9964 pTP 1, 2, 5, 6
50-UAGUCUUGCAUGAGCCUUUCUACCG-30
pTP-si7 50-ACUACCUCUUUCAGCGCCUGCGAAA-30 9103–9127 pTP 1, 2, 5, 6
50-UUUCGCAGGCGCUGAAAGAGGUAGU-30
pTP-si8 50-GAAAUUGAUUCUGUCGAACUCUCUU-30 8789–8813 pTP 1, 2, 5, 6
50-AAGAGAGUUCGACAGAAUCAAUUUC-30
aGenBank ID: AC_000008.
bSerotypes displaying 100% target site complementarity.
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Cycler 480 system (Roche Diagnostics, Vienna, Austria) with the
following cycling parameters: heating to 95 C for 1 min followed
by 50 cycles at 95 C for 15 s and 60 C for 1 min. Data were ana-
lyzed using the LightCycler 480 software. Control included with
every assay consisted of a ‘no template control’ (no DNA added).
2.7. Determination of adenovirus genome copy numbers
3e+04 A549 cells were seeded into the wells of 96-well plates,
and reverse transfected with siRNAs at concentrations ranging
from 0.04 nM to 30 nM. Transfection conditions were as described
under 2.5., except that reporter plasmid DNA was omitted. After
24 h, cells were infected with Ad1, Ad2, Ad5, or Ad6 at an MOI of
0.01 TCID50/cell. Samples were collected at 2, 4, and 6 days post-
infection. Viral DNA was isolated using a QIAamp DNA Blood Mini
Kit (QIAGEN). Ad5 genome copy numbers were determined by
qPCR, using the following TaqMan primer/probe set directed
against the viral E1A region: E1A-fwd 50-GACGGCCCCCGAAGATC-
30, E1A-rev 50-TCCTGCACCGCCAACATT-30, and E1A-p 50-CGAGGA
GGCGGTTTCGCAGA-30. The setup of qPCR assays and the cycling
parameters were the same as described above. For each reaction,
1 lL of isolated DNA was used. Adenovirus genome copy numbers
were calculated by using serial dilutions of an adenoviral reference
DNA as a standard.
2.8. Determination of numbers of infectious virus particles
To liberate the viruses from the cells, 96-well plates containing
cells and viruses were subjected to three freeze–thaw cycles. Crude
lysates were cleared by centrifugation of the plates for 15 min at
2800 rpm. The numbers of infectious virions were determined on
A549 cells by TCID50 assays.
2.9. Cell viability
The experimental setup for the determination of the viability of
infected cells was as described for other virus inhibition experi-
ments, except that A549 cells were infected at higher MOIs of 2
TCID50/cell, 4 TCID50/cell, or 6 TCID50/cell. Metabolic activity as a
measure of cell viability was determined at 6 days post-infection
by performing an MTS assay (CellTiter 96 Aqueous Non-Radioac-
tive Cell Proliferation Assay), according to the manufacturer’s
instructions (Promega). Absorbance was determined at 490 nm
on a Wallac Victor 1420 Multilabel Counter (Perkin Elmer).
2.10. Statistical analysis
All the data are expressed as mean ± standard deviation (SD). To
test for statistical signiﬁcance, one-way ANOVA corrected with
Bonferroni’s post hoc test was applied. A p value of <0.05 was con-
sidered statistically signiﬁcant.
3. Results
3.1. Identiﬁcation of best-performing siRNAs directed against E1A,
DNA polymerase, pTP, IVa2, hexon, and protease
To analyze which adenoviral processes may constitute useful
targets for RNAi-mediated inhibition of adenovirus multiplication,
we designed a set of siRNAs targeting the E1A, DNA polymerase,
pTP, IVa2, hexon, and protease mRNAs (Table 1). E1A siRNAs were
designed to target E1A-12S and also E1A-13S splice isoforms. With
the exception of pTP-si1 to pTP-si4, all siRNAs were 25-mer, blunt-
ended siRNAs carrying the Invitrogen ‘‘Stealth’’ modiﬁcation. pTP-si1 to pTP-si4 were 21-mer, unmodiﬁed siRNAs carrying 2 nt TT
overhangs at their 30 ends. To screen for the best-performing siRNA
of each group, we employed a dual-luciferase assay-based system.
The respective target sequences were individually inserted into the
30 UTR of a plasmid-located Renilla luciferase gene. The DNA poly-
merase, pTP, IVa2, hexon, and protease siRNAs, together with the
respective reporter vectors, were used to co-transfect HEK293
cells. Knockdown of Renilla luciferase expression in relation to
the expression of a ﬁreﬂy luciferase gene located on the same plas-
mid was determined in dual-luciferase assays. The silencing capac-
ity of the E1A siRNAs was assessed in A549 cells because promoter
activities of the reporter vectors turned out to be altered upon
silencing of the endogenous E1A gene present in HEK293 cells
(Graham et al., 1977) (data not shown). For all target mRNAs, we
identiﬁed siRNAs enabling a knockdown of P78% at a concentra-
tion of 30 nM (Fig. 1). The best-performing siRNAs of each group,
i.e., pTP-si8, Pol-si2, Hex-si2, E1A-si3, Iva2-si2, and Prot-si1, were
selected for further characterization.
3.2. SiRNAs decrease mRNA levels directly or indirectly
The dual-luciferase assay-based screening system was em-
ployed to select the best-performing siRNAs of each group. Next,
we investigated whether the selected siRNAs were able to knock-
down gene expression during an adenovirus infection of A549
cells. Cells were transfected with the siRNAs at a concentration
of 10 nM, and then infected with Ad5 at an MOI of 0.01 TCID50/cell.
Target mRNA levels were determined by RT-qPCR, using primers
speciﬁc for the individual mRNAs (Fig. 2A). The highest silencing
rates (93–97%) were observed for the E1A-, DNA polymerase-,
pTP-, and IVa2-targeting siRNAs. Silencing of the hexon and prote-
ase genes was less pronounced (79–87%). Except for the difference
in residual hexon and pTP mRNA levels, the differences between
hexon or protease mRNA levels and those of all other early genes
were statistically signiﬁcant.
As the pTP, DNA polymerase, and IVa2 mRNAs share a common
30 part (Supplementary Fig. 1), and the DNA polymerase target site
is also part of the pTP mRNA, IVa2- and DNA polymerase-directed
siRNAs were therefore expected to concomitantly silence pTP/DNA
polymerase/IVa2 and pTP/DNA polymerase, respectively. Further-
more, siRNA-mediated silencing of early genes was expected indi-
rectly to affect the expression of those middle or late genes for
which expression is known to depend on early viral gene products.
Thus, we also determined the effect of the E1A-, pTP-, DNA poly-
merase-, and IVa2-targeting siRNAs on the expression of the other
genes. Silencing of E1A resulted in a marked reduction in the
expression of all other genes (Fig. 2B). This can be attributed to
the central role of E1A in activating the expression of downstream
genes.
Silencing of the E1A gene actually resulted in a greater reduc-
tion in the expression of hexon and protease than did direct silenc-
ing of these genes by the hexon and protease siRNAs (compare
Fig. 2A and B). As expected, the DNA polymerase-directed siRNA
also silenced the pTP gene, and indirectly also affected the expres-
sion of all other genes (Fig. 2C). This ﬁnding is in accordance with
the dependency of IVa2 and ML transcription on the replication of
the adenoviral genome, for which DNA polymerase expression is
mandatory (Flint, 1986; Iftode and Flint, 2004; Shaw and Ziff,
1980). The same holds true for silencing of pTP (Fig. 2D), which
is also essential for virus DNA replication, and consequently activa-
tion of transcription from the other promoters. Although the pTP
siRNA target site is absent from DNA polymerase mRNA, pTP
silencing also decreased DNA polymerase mRNA levels, albeit to
a lesser extent than DNA polymerase silencing did. This reduction
can be attributed to the inhibition of DNA replication by the pTP
siRNA, and consequently decreased DNA polymerase gene copy
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200 D. Kneidinger et al. / Antiviral Research 94 (2012) 195–207numbers. As expected, the IVa2 siRNA led to a reduction not only in
IVa2, but also in pTP and DNA polymerase mRNA levels (Fig. 2E).
Since transcription from the MLP is highly activated by the IVa2
protein (Tribouley et al., 1994), ML transcript levels were also indi-
rectly decreased.3.3. SiRNAs decrease Ad5 genome copy numbers, and also the output of
infectious virus progeny
In order to investigate the gene silencing effect of the individual
siRNAs on adenovirus replication, A549 cells were transfected with
the siRNAs at a concentration of 10 nM and infected as before. At
2 days post-infection, Ad5 genome copy numbers were determined
by qPCR, using primers directed against the E1A gene (Fig. 3A).
With the exception of the hexon and protease siRNAs, all siRNAs
effectively inhibited adenovirus replication. The highest inhibition
rate was achieved with the DNA polymerase siRNA, which de-
creased Ad5 genome copy numbers on average by approximately
2.5 orders of magnitude (99.6%). The failure of the hexon and pro-
tease siRNAs to decrease virus genome copy numbers was not sur-
prising, because a reduction in hexon and protease levels is not
expected to affect viral DNA replication.
Next, we evaluated the performance of those siRNAs that were
expected directly or indirectly to affect the output of viral DNA (i.e.,
E1A, DNA polymerase, pTP, and IVa2 siRNAs) in a time-course
experiment spanning 6 days in which Ad5 was allowed to spread
throughout the cultures (Fig. 3B). As expected, viral genome copy
numbers were also decreased at later time points. We repeated
the experiments with higher siRNA concentrations (30 nM and
90 nM) and obtained comparable results (data not shown). The
inhibition rate at late time points may be generally underesti-
mated; although the cells were infected with Ad5 at a low MOI
of 0.01 TCID50/cell, the high burst size of adenovirus rapidly leads
to infection of the entire culture. This prevents an exponential in-
crease in virus multiplication at later time points, in those cultures
in which replication is not attenuated by siRNAs.
The impact of siRNAs on viral processes other than DNA replica-
tion is not fully elucidated by the measurement of virus genome
copy numbers. Thus, we also determined the output of infectious
virus progeny. Cells were transfected and infected as described
above, and the numbers of infectious virus particles at 48 h post-
infection were determined (Fig. 4). We observed that hexon and
protease siRNAs inhibited the production of infectious virus prog-
eny by approximately 1.3 and 0.8 orders of magnitude (94.9% and
83.1%), respectively. However, the other siRNAs led to an evenhigher decrease in virus titers of up to 2.8 orders of magnitude
(99.8%).
Taken together, our data indicate that silencing of early or inter-
mediate genes seems to be more effective in terms of reducing the
output of viral DNA, and also the number of infectious virus prog-
eny, than is silencing of late genes. Computational calculation of
the target site accessibility of the DNA polymerase siRNA, using
the RNAxs software tool, suggested high accessibility of the entire
region embedding the Pol-si2 target site. Target site accessibility
has been reported to correlate with high effectiveness of siRNAs
(Tafer et al., 2008; Westerhout and Berkhout, 2007). Thus, we spec-
ulated that siRNAs capable of binding to target sites in the imme-
diate vicinity of, or overlapping, the target site of the Pol-si2 siRNA
may allow simlar or even better knockdown of DNA polymerase
gene expression than Pol-si2. Thus we designed three more such
siRNAs (Fig. 5A). However, none of them proved superior to the
Pol-si2 siRNA (Fig. 5B). The functionality of Pol-si2 was also vali-
dated by comparing its activity not only to that of a universal
non-targeting control siRNA but also to that of a scrambled version.
No change in the inhibition rate was observed (Supplementary
Fig. 2). The inhibitory effect of Pol-si2 was also shown to be
dose-dependent (Fig. 6). The silencing capacity of low siRNA con-
centrations may even be underestimated in some experiments;
in control experiments employing ﬂuorescence-labeled siRNAs,
the transfection efﬁciency decreased signiﬁcantly at concentra-
tions of <5 nM (data not shown). Thus, low siRNA concentrations
do not truly reﬂect the silencing capacity, because signiﬁcant num-
bers of cells contain no siRNA.
The target sequence of the DNA polymerase siRNA is also pres-
ent in the mRNAs of the other members of adenovirus species C
(i.e., Ad1, Ad2, and Ad6), all of which commonly account for life-
threatening disseminated adenovirus disease. Consequently, the
inhibitory effect of the DNA polymerase siRNA was not restricted
to Ad5. Replication of Ad1, Ad2, and Ad6 was also efﬁciently inhib-
ited (Supplementary Fig. 3).3.4. Treatment with individual siRNAs or combinations of siRNAs
results in a comparable decrease in the numbers of infectious virus
particles
Given the dependency of intermediate or late adenoviral gene
expression on certain early viral gene products, simultaneous
silencing of different adenoviral genes may have synergistic effects
on the inhibition of virus multiplication. We therefore performed
virus inhibition experiments using combinations of siRNAs. In all
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Fig. 2. siRNAs decrease mRNA levels directly and indirectly. A549 cells were transfected with siRNAs directed against the E1A, DNA polymerase (Pol), pTP, IVa2, hexon (Hex),
and protease (Prot) genes, or a non-targeting control siRNA (neg. ctrl.) at a concentration of 10 nM, and then infected with Ad5 at an MOI of 0.01 TCID50/cell. Levels of direct
targets (A) or indirect targets such as the E1A (B), DNA polymerase (C), pTP (D), and IVa2 (E) mRNAs were determined by RT-qPCR. Relative mRNA levels in comparison to a
non-targeting siRNA are shown. Values represent mean ± SD of three independent experiments, each performed in triplicate. For each experiment, real-time qPCR
quantiﬁcation was performed in duplicate. p < 0.05, p < 0.001.
D. Kneidinger et al. / Antiviral Research 94 (2012) 195–207 201of these experiments, we used a total siRNA concentration of
10 nM, i.e., combined siRNAs were employed at a concentration
of 5 nM each. As a control, cells were transfected with the individ-
ual siRNAs at a concentration of 10 nM. To correct for potential sat-
uration effects (e.g., during transfection and/or RISC loading of
siRNAs), cells were also transfected with a combination of 5 nM
individual targeting siRNA and 5 nM non-targeting control siRNA.
The numbers of infectious virus particles were determined at
48 h post-infection by TCID50 assay (Fig. 7). As shown in Fig. 7B,
the superior anti-adenoviral effect mediated by the DNA polymer-
ase siRNA was not enhanced by simultaneous targeting of those
mRNAs whose generation depends on the function of the DNA
polymerase, e.g., the IVa2 or hexon genes. Similarly, combined
E1A and DNA polymerase silencing did not further decrease virus
titers (Fig. 7A). The same held true for all other siRNA combina-
tions. In general, combining a highly effective siRNA with a less
well-performing siRNA led to an intermediate inhibition rate, oran inhibition rate equal to the one caused by the individual bet-
ter-performing siRNA. Moreover, the anti-adenoviral effect of an
individual siRNA was not reduced by halving its concentration
upon combination with an equal concentration of non-targeting
negative control siRNA.
We speculated that possible synergistic effects may have been
undetectable, because the cells were harvested at a relatively early
time point (48 h post-infection). However, they might become
detectable at later time points, when the virus was allowed to
spread throughout the culture. We hypothesized that combina-
tions comprising the E1A siRNA on the one hand, and siRNAs tar-
geting mRNAs originating from other early/middle genes on the
other, would be most likely to cause a synergistic effect. We there-
fore repeated the virus inhibition experiment using the respective
siRNA combinations, and determined Ad5 genome copy numbers
at 6 days post-infection. However, we did not detect any synergis-
tic effects at this late time point (Supplementary Fig. 4). We also
AB
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Fig. 3. Impact of siRNAs on viral DNA replication and virus spreading. (A) A549 cells were transfected with siRNAs directed against the E1A, DNA polymerase (Pol), pTP, IVa2,
hexon (Hex), and protease (Prot) genes, or a non-targeting control siRNA (neg. ctrl.) at a concentration of 10 nM, and then infected with Ad5 at an MOI of 0.01 TCID50/cell.
Virus genome copy numbers were determined at 48 h post-infection by qPCR, using E1A-speciﬁc primers. Values represent mean ± SD of three independent experiments,
each performed in triplicate. For each experiment, real-time qPCR quantiﬁcation was performed in duplicate. p < 0.001. (B) Long-term infection of A549 cells with Ad5 at an
MOI of 0.01 TCID50/cell, and treatment with 10 nM of the indicated siRNAs. Virus genome copy numbers were determined at time points 0, 2, 4, and 6 days post-infection by
qPCR. Representative data from at least three independent experiments, each performed in triplicates, are shown (mean ± SD; n = 3). For each experiment, real-time qPCR
quantiﬁcation was performed in duplicate. p < 0.01.
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Fig. 4. siRNAs decrease the numbers of infectious virus particles. A549 cells were
transfected with siRNAs directed against the E1A, DNA polymerase (Pol), pTP, IVa2,
hexon (Hex), and protease (Prot) genes, or a non-targeting control siRNA (neg. ctrl.)
at a concentration of 10 nM, and then infected with Ad5 at an MOI of 0.01 TCID50/
cell. Numbers of infectious virus particles at 48 h post-infection were determined
on A549 cells by TCID50 assays. Representative data from three independent
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Although there was a slight trend toward somewhat increased
inhibition for some combinations, none of these differences were
statistically signiﬁcant, and under no conditions did any combina-
tions of siRNAs result in a higher inhibition rate than the inhibition
rate caused by Pol-si2 when applied alone (Supplementary Fig. 5).
3.5. SiRNAs increase the viability of infected cells to different extents
Next, we quantitatively assessed the impact of Ad5 gene silenc-
ing on the viability of infected cultures. We transfected A549 cells
with the siRNAs at a concentration of 10 nM as before, and then in-
fected themwith Ad5 at a higher MOI (4 TCID50/cell) to ensure pro-
nounced cell killing. We determined the metabolic activity as a
measure of cell viability at 6 days post-infection, by means of an
MTS assay (Fig. 8). As expected, the siRNAs, although greatly
decreasing the output of virus progeny, were not capable of pre-
venting already infected cells from cell death. This was also clearly
deducible from experiments in which the overall appearance of in-
fected cultures was assessed by crystal violet staining (data not
shown).
However, all siRNAs were capable of prolonging cell survival, al-
beit to different extents. This protective effect was most pro-
Fig. 5. Differential inhibition of Ad5 replication by DNA polymerase siRNAs binding in the immediate vicinity of, or overlapping, the Pol-si2 target sequence. (A) Region of the
DNA polymerase open reading frame (indicated as DNA pol) targeted by siRNAs Pol-si2, Pol-si4, Pol-si5, and Pol-si6. The DNA sequences corresponding to the individual
siRNA target sites on the target mRNAs are given below. The nucleotides corresponding to the seed regions of the respective siRNAs are shaded in grey. (B) A549 cells were
transfected with the viral DNA polymerase-directed siRNAs or a non-targeting control siRNA (neg. ctrl.) at a concentration of 10 nM, and then infected with Ad5 at an MOI of
0.01 TCID50/cell. Virus genome copy numbers from triplicate infections (mean ± SD; n = 3) were determined at 48 h post-infection by qPCR using E1A-speciﬁc primers.
p < 0.001.
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Fig. 6. Dose-dependent decrease in Ad5 genome copy numbers mediated by the
DNA polymerase siRNA. A549 cells were transfected with the DNA polymerase
siRNA or a non-targeting control siRNA (neg. ctrl.) in decreasing concentrations as
indicated, and then infected with Ad5 at an MOI of 0.01 TCID50/cell. Virus genome
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cells displayed severe cytopathic effects and were already partially
detached from the culture vessels, the culture viability was
remarkably high (>80%) at 6 days post-infection. We repeated the
experiment using lower and higher MOIs (2 TCID50/cell and 6
TCID50/cell, respectively) and obtained comparable results with a
tendency towards higher and lower protection at decreased and in-
creased MOIs, respectively (data not shown). The observed protec-
tive effect of the E1A siRNA could not be attributed to a possible
unspeciﬁc general increase in cellular metabolic activity, because
neither the E1A siRNA nor any of the other siRNAs altered the via-
bility of uninfected cells (Supplementary Fig. 6). Thus, although the
E1A siRNA did not inhibit the output of infectious virus progeny asefﬁciently as did the DNA polymerase siRNA, it enhanced the via-
bility of infected cells and kept them alive for a prolonged time
period.
4. Discussion
In the present study, we evaluated a larger panel of potential
targets, and also determined the inhibitory effect of siRNAs on
wild-type adenovirus. SiRNAs directed against the E1A, DNA poly-
merase, pTP, and IVa2 transcripts were all capable of efﬁciently
silencing the respective genes in the course of an adenovirus infec-
tion. By contrast, although having displayed a comparable silenc-
ing capacity in luciferase reporter assays, the hexon- and
protease-directed siRNAs, showed only a limited capacity to reduce
the number of ML transcripts. This observation can be attributed to
the markedly higher amounts of hexon and protease mRNAs gen-
erated from the particularly strong MLP, in comparison with the
mRNA levels of the other genes. This high number of MLP-derived
late mRNAs may become even more problematic in RNAi-based at-
tempts to inhibit adenovirus multiplication, because the virus-
associated RNAs (VA-RNAs) I and II (non-coding RNAs produced
in low amounts during the early stages of infection, but in vast
amounts at later time points) appear to counteract RNAi. This ef-
fect is thought to be partially caused by the incorporation into
and saturation of the RISC by VA-RNA subfragments, which behave
like miRNAs (Andersson et al., 2005). Thus, siRNA-mediated inhibi-
tion of adenovirus gene expression during the early stages of infec-
tion may generally be more beneﬁcial than inhibition of late-stage
gene expression. In this regard, inhibition of viral DNA replication
may be particularly advantageous, because a decrease in viral gen-
ome copy numbers should signiﬁcantly lower VA-RNA gene copy
numbers. In the present study, we observed such an indirect effect
when measuring pTP mRNA levels following knockdown of viral
DNA polymerase expression. Although not a direct target of the
DNA polymerase siRNA, the pTP mRNA levels dropped signiﬁcantly
as a consequence of reduced genome (and pTP gene) copy numbers
(Fig. 2D).
Effective knockdown of hexon gene expression may be even
more complicated, because hexon mRNA-directed siRNAs target
not only the hexon, but also the pVI mRNA. This is caused by the
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Fig. 7. Effect of combinatorial silencing of Ad5 genes on virus output. A549 cells were transfected with the indicated siRNAs either alone or in combination. SiRNA
combinations for E1A (A), DNA polymerase (B), pTP (C), IVa2 (D), hexon (E), and protease (F) are depicted. For all transfections, the total concentration of siRNA was 10 nM. For
combinations, each siRNA was employed at a concentration of 5 nM. As a control, cells were transfected with the individual siRNAs alone at a concentration of 10 nM, or as a
mix of 5 nM targeting siRNA and 5 nM non-targeting negative control siRNA. Subsequently, cells were infected with Ad5 at an MOI of 0.01 TCID50/cell, and cells and
supernatants were harvested at 48 h post-infection. Numbers of infectious Ad5 particles of triplicate infections were determined on A549 cells by TCID50 assays (mean ± SD;
n = 3).
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open reading frame on all pVI transcripts. Thus, hexon mRNA-tar-
geting siRNAs may be partially sequestered away from their actual
target by the pVI mRNA, thereby becoming limiting in hexon
silencing. The same holds true for the protease siRNA (which con-
comitantly silences all other genes of the L3 region, i.e., pVI and
hexon), the IVa2 siRNA (which additionally binds to the DNA poly-
merase and pTP mRNAs), and the DNA polymerase siRNA (whichconcomitantly silences the pTP gene). However, the mRNA levels
of these genes, especially those coding for DNA polymerase and
pTP, are far lower than those produced by the MLP, and siRNAs
may less easily become limiting. Hexon gene silencing was previ-
ously demonstrated to be as effective in inhibiting adenovirus mul-
tiplication as was silencing of the early E1A gene (Eckstein et al.,
2010). This may be attributed to the fact that the mutant virus used
was deﬁcient in the E1B-55K gene. E1B-55K has been reported to
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Fig. 8. SiRNAs increase the viability of infected cells. A549 cells were transfected
with siRNAs directed against the E1A, DNA polymerase (Pol), pTP, IVa2, hexon
(Hex), and protease (Prot) genes, or a non-targeting control siRNA (neg. ctrl.) at a
concentration of 10 nM, and then infected with Ad5 at an MOI of 4 TCID50/cell. An
MTS assay was performed at 6 days post-infection. The viability of cells from
triplicate infection experiments (mean ± SD; n = 3) was calculated in relation to the
viability of mock-infected cells. p < 0.001.
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(Woo and Berk, 2007). Thus, and consequently, lower amounts of
ML mRNAs may accumulate in the cytoplasm of cells infected with
this mutant virus.
In the present study, we speculated that silencing of early rather
than late adenoviral genes would be more effective in inhibiting
adenovirus multiplication. We observed that indirect inhibition
of hexon and protease gene expression by silencing of genes for
which expression activates ML transcription was more effective
than was direct targeting of the hexon and protease transcripts
(Fig. 2B–E). Importantly, this included E1A silencing. It was previ-
ously reported that E1A promotes adenoviral DNA replication, even
when present at very low concentrations (Hitt and Graham, 1990).
The rather disappointing anti-adenoviral effect obtained with an
E1A-directed siRNA (Eckstein et al., 2010) was ascribed to this fact.
In the present study, the E1A siRNA employed was obviously po-
tent enough efﬁciently to decrease not only the E1A mRNA levels,
but also, indirectly, the mRNA levels of E1A downstream targets
such as the DNA polymerase, pTP, IVa2, hexon, and protease genes
(Fig. 2B). Consequently, E1A silencing markedly inhibited the syn-
thesis of viral DNA, and also the generation of infectious virus
progeny (Figs. 3 and 4).
The E1A siRNA also substantially improved the viability of the
infected cultures, as measured by MTS assay (Fig. 8). This effect
was not immediately evident by visual inspection of the cultures,
because the siRNA failed to prevent certain adenovirus-related
cytopathic effects. The increase in cell viability may be derived
from prevention of the well-known toxic effects caused by the
main E1A splice isoforms, which eventually drive cells into apopto-
sis (Cuconati et al., 2002; Lowe and Ruley, 1993; White, 2001). Cell
viability was only moderately improved upon silencing of the other
early genes. This contradicts a possible indirect E1A siRNA-medi-
ated protective effect (which may occur following blockage of viral
DNA replication), and a consequent decrease in the copy numbers
of other genes, such as the adenovirus death protein (ADP) gene,
which is required for efﬁcient cell lysis and virus release (Tollefson
et al., 1996). The inability of the E1A siRNA used by Eckstein et al.
(2010) to increase cell viability may also be partially related to the
absence of the anti-apoptotic E1B genes from the mutant virus
employed.
A reduction in infectious virus progeny was also achievable by
knockdown of IVa2 gene expression. However, the fact that IVa2-
directed siRNAs silenced not only the IVa2 gene, but also the
DNA polymerase and pTP genes, makes it impossible to distinguishwhether the main inhibitory effect was caused by blockage of
IVa2-mediated viral processes (i.e., activation of late gene expres-
sion or DNA packaging), or by inhibition of viral DNA synthesis.
The other 2 siRNAs targeting the viral DNA replication machinery
(i.e., the pTP and DNA polymerase genes) were among the most
effective in inhibiting adenovirus multiplication. This ﬁnding does
not exclude IVa2-mediated viral processes as potential targets for
RNAi-mediated intervention, but clearly establishes adenoviral
DNA replication as a key target for the inhibition of adenovirus
multiplication.
Combinatorial targeting of different viral transcripts has occa-
sionally been reported to lead to synergistic effects (Chen et al.,
2005; ter Brake et al., 2006). In the present study, combinatorial
targeting of different adenoviral transcripts did not further de-
crease virion production. This observation is in accordance with
similar ﬁndings of Eckstein et al. (2010). It is possible that, in some
cases, targeting of 2 distinct transcripts may be redundant. For
example, it is conceivable that reducing hexon protein, and also
viral genome numbers, is of no additional beneﬁt, because the out-
put of DNA-containing virions will remain unchanged regardless of
whether high or low amounts of structural proteins are produced.
Nevertheless, synergistic effects are conceivable for other combi-
nations. At least at high siRNA concentrations, competitive effects
during lipofection or saturation of RISC are conceivable reasons for
the failure to observe synergistic effects. To correct for these, we
compared the inhibitory effects of combined siRNAs to those of
individual siRNAs, and also to individual siRNAs combined with
non-targeting negative control siRNA. Throughout these experi-
ments, we maintained a constant concentration of each siRNA,
regardless of whether it was combined with another targeting siR-
NA. However, we did not observe any synergistic effects. The
repeatedly observed failure to produce synergistic effects upon
combining siRNAs has been suspected to be attributable to the
competition between siRNAs for RISC loading (Castanotto et al.,
2007; Formstecher et al., 2006; Koller et al., 2006). It is possible
that some of the siRNAs employed in the present study were more
efﬁciently incorporated into the RISC, and were therefore able to
outcompete the others.
Animal studies will eventually reveal how efﬁciently the siRNAs
selected in this study can inhibit adenovirus multiplication in vivo.
Delivery of siRNAs into living organisms is much more challenging
than delivery into cells in vitro. However, a number of delivery
vehicles have been developed over the past years which have con-
tinuously improved the delivery rates in vivo (Rettig and Behlke,
2011), and RNAi has successfully been applied to condemn virus
replication in vivo (Arbuthnot, 2010; Haasnoot et al., 2007; Zhou
and Rossi, 2011). The results reported here may also help to gener-
ate viral vectors for the efﬁcient expression and delivery of anti-
adenoviral siRNAs in the form of shRNAs or artiﬁcial miRNAs, a po-
tential alternative way of eliciting anti-adenoviral RNAi in infected
cells.5. Conclusion
Taken together, our data indicate that: (i) highly potent siRNAs
are able to inhibit adenovirus multiplication, making them attrac-
tive anti-adenoviral drug candidates; (ii) silencing of early adeno-
viral genes may be more beneﬁcial than silencing of late genes;
(iii) silencing of certain early genes can indirectly reduce late gene
products more efﬁciently, or at least as well as, direct silencing of
the late genes; (iv) adenoviral infections may be more effectively
treated by reduction of adenoviral DNA than by reduction of the
proteinaceous components of the virion; (v) the adenoviral DNA
replication machinery, and in particular the DNA polymerase gene,
constitutes a key target for RNAi-mediated inhibition of adenovirus
206 D. Kneidinger et al. / Antiviral Research 94 (2012) 195–207multiplication; and (vi) silencing of the E1A gene (although less
effective than silencing of the DNA polymerase gene in preventing
the generation of virus progeny) should not be excluded as a po-
tential strategy, because it may impair virus spread in vivo, by pro-
longing the survival of infected cells.
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